Regional Minister Irujo presents the Navarra Health Cluster
This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.
[Noáin, Spain, June 27, 2022] 3P Biopharmaceuticals (3P), a leading CDMO organization specializing in developing cGMP processes and manufacturing biological products, launches the Navarra Health Cluster together with seven companies in the sector.
The initiative, which stems from the sector’s demand and is led by a driving group, is now open to other companies and entities interested in participating.
This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy.
The constitution is being promoted with the support of the Department of Economic and Business Development, aiming to strengthen and increase the sector’s competitiveness. Through measures and lines of impulse and support for competitiveness, from the General Directorates of Business Policy, International Projection and Employment and Industry, Energy and Strategic Projects S4, as well as from Sodena and CEIN, the aim is to promote entrepreneurship, consolidation and business growth.
The initiative is led by eight companies: 3P Biopharmaceuticals, Cinfa, Creo Medical, Idifarma, Innoupfarma, Palo Biofarma, Qubepharma Group and Telum Therapeutics. The process has included numerous driving group working committees meetings to prepare the project. It is now open to other companies and organizations in the sector in Navarre, who are called upon to participate and find a person to manage and promote the project.
Irujo pointed out that “Navarre has a competitive healthcare sector, capable of bringing innovative and accessible solutions to the market for all healthcare challenges. The health sector is key to the economy of Navarre and is also a generator of knowledge, welfare and quality employment”. He also recalled that “Navarre is a pioneer at the national level in the approval of a Comprehensive Strategy for Personalized Medicine, integrating the areas of health, innovation and economic development”, an area that has been supported since 2017 by the R&D calls for strategic projects S4 GEMA (“genomics and advanced medicine”).
Dámaso Molero, CEO of 3P, points out “Our challenges as a region and as a cluster are to bring to the market all these high-quality initiatives in personalized medicine, gene therapy, recombinant proteins, monoclonal antibodies, etc… We must promote science, knowledge and the development of researchers to make Navarre an attractive region and a focus of attention for students and professionals in the sector and their families, scientists, companies, investment funds and investors; that is the great challenge we face”.
Navarra has great strengths in the entire value chain, from scientific production, product development and quality clinical services, a value chain that employs 31,508 people, most of them in healthcare services (27,981), but with 2,465 people working in the healthcare industry and 1,065 in research.
The main industrial area of the health sector is Biopharma, which represents 64% of the industry’s total turnover, with a business fabric comprising of 29 companies that are growing in importance and a turnover of 504 million euros in 2020. The fastest-growing segment in terms of the number of companies is Medical Devices, with 41 companies and a turnover of 60.6 million euros in 2020. Prevention and Wellness is the second most crucial area of the industry linked to Health, with 13 companies representing almost 29% of the total sector turnover of 228.5 million euros. And has opportunities for development and the creation of new initiatives in connection with the healthy eating and personalized nutrition sector.
The turnover of the health sector industry increased by 20.3% in 2020 compared to 2016, which means 134 million euros more turnover, reaching 793 million euros.
About 3P Biopharmaceuticals
3P Biopharmaceuticals is a market-leading CDMO (Contract Development and Manufacturing Organization) specializing in process development and GMP (Good Manufacturing Practice) manufacturing biologics and cell therapy products. 3P offers solutions for all stages of new drug and biosimilar development and manufacturing, including cell line and process development, analytical methods development, pre-clinical and clinical supply and commercial manufacturing. For further information: http://www.3pbio.com/
3P Biopharmaceuticals contact:
Communications & Marketing at 3P Biopharmaceuticals
Phone: + 34 948 346 480